NeuroSense Therapeutics to Appeal Nasdaq Delisting Notice
Ticker: NRSNW · Form: 6-K · Filed: Jun 21, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, Nasdaq, appeal
Related Tickers: NSRS
TL;DR
Nasdaq wants to delist NeuroSense, but they're fighting back.
AI Summary
On June 21, 2024, NeuroSense Therapeutics Ltd. received a delisting notice from Nasdaq. The company intends to appeal this decision to regain compliance with Nasdaq's listing requirements.
Why It Matters
This filing indicates a potential risk to NeuroSense's listing on a major stock exchange, which could impact its ability to raise capital and its stock's liquidity.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major exchange like Nasdaq poses a significant risk to the company's stock viability and future funding.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — The company that received the delisting notice.
- Nasdaq (company) — The stock exchange that issued the delisting notice.
- June 21, 2024 (date) — The date the delisting notice was issued.
FAQ
What is the reason for the delisting notice from Nasdaq?
The filing does not specify the exact reason for the delisting notice, only that NeuroSense Therapeutics Ltd. received it and intends to appeal.
What is NeuroSense Therapeutics Ltd.'s plan regarding the delisting notice?
NeuroSense Therapeutics Ltd. intends to appeal the delisting notice from Nasdaq.
When was the delisting notice issued?
The delisting notice was issued on June 21, 2024.
What form was filed with the SEC regarding this event?
A Form 6-K was filed with the SEC on June 21, 2024, reporting the delisting notice and the company's intent to appeal.
Is there a specific exhibit attached to the 6-K filing?
Yes, Exhibit 99.1, a press release titled 'NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal,' is furnished with the Form 6-K.
Filing Stats: 261 words · 1 min read · ~1 pages · Grade level 9.9 · Accepted 2024-06-21 16:42:19
Filing Documents
- ea0208261-6k_neurosense.htm (6-K) — 11KB
- ea020826101ex99-1_neurosense.htm (EX-99.1) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-054830.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: June 21, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 3